Sarah Miyata, NP
Acute Care · Chicago, ILNPI 1205862919
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Seagen Inc. at 54.8% of the total. Reporting peaked in 2023 at $5,944 and has fallen 99.4% since, to $34 in 2025. Among acute care clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 24 payments — averaging $461.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$6K
- Lilly USA, LLC$4K
- Incyte Corporation$840
- Morphosys, US Inc.$34
- AstraZeneca$34
- Regeneron Healthcare Solutions, Inc.$33
- plus $13 from 1 others
What the payments were for
- Consulting fees$4,89044%
- Speaking & faculty fees$5,84553%
- Travel & lodging$230%
- Food & beverage$3233%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 15 | $6,078 |
| Lilly USA, LLC | 4 | $4,050 |
| Incyte Corporation | 1 | $840 |
| Morphosys, US Inc. | 1 | $34 |
| AstraZeneca | 1 | $34 |
| Regeneron Healthcare Solutions, Inc. | 1 | $33 |
| Bristol Myers Squibb | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADCETRIS$5,956
How this compares
$11,081 in reported general payments places this provider in the 95th percentile of 461 acute care providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 81 | $1,177,249 |
| RevlimidLenalidomide | 32 | $599,170 |
| ImbruvicaIbrutinib | 30 | $450,075 |
| JaypircaPirtobrutinib | 21 | $441,864 |
| CalquenceAcalabrutinib Maleate | 18 | $273,124 |
| JakafiRuxolitinib Phosphate | 13 | $216,223 |
| VenclextaVenetoclax | 15 | $145,137 |
| Fluconazole | 20 | $787 |
| Acyclovir | 87 | $600 |
| ValacyclovirValacyclovir Hcl | 11 | $481 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 90 | $225 |
| Gabapentin | 19 | $218 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $13 | $599,17032 claims |
| Lilly USA, LLCJaypirca | $4,050 | $441,86421 claims |
| AstraZenecaCalquence | $34 | $273,12418 claims |
| Incyte CorporationJakafi | $840 | $216,22313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 461 acute care providers in Illinois.
Other acute care in Chicago
- Tedra GrayChicago$78K
- Gwen CassidyChicago$46K
- Erin DarguzasChicago$17K
- Katie MeadorChicago$10K
- Viktoriya KaganChicago$8K
- Laura RitchieChicago$5K
- Christine Joy LocquiaoChicago$5K
- Janice AmslerChicago$5K
- Julie MudgeChicago$3K
- Tonia JacobChicago$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.